Inactive Instrument

All News Qiagen Nasdaq

Equities

Qiagen N : 2024 QIAGEN N.V. Annual General Meeting of Shareholders Presentation	05-08	PU
Qiagen N : 2023 Annual Report 2023 Annual Financial Report	05-08	PU
Qiagen, US FBI to Jointly Develop Digital PCR Assay for Forensics	05-08	MT
QIAGEN partners with FBI to develop digital PCR assay for QIAcuity for use in forensics	05-07	AQ
QIAGEN Partners with FBI to Develop Digital PCR Assay for QIAcuity for Use in Forensics	05-07	CI
Qiagen N : Q1 2024 Results Investor Introduction	05-03	PU
QIAGEN enhances bioinformatics workflows with new secondary analysis solution for oncology and inherited disease applications	05-02	AQ
QIAGEN Announces the Availability of QCI Secondary Analysis	05-02	CI
Qiagen N : First Quarter 2024 SEC Filing	05-02	PU
QIAGEN NV : Berenberg reaffirms its Buy rating	04-30	ZD
QIAGEN : A decent start to 2024; guidance unchanged	04-30
QIAGEN NV : Deutsche Bank reiterates its Buy rating	04-30	ZD
Qiagen Seeks Acquisitions	04-30	CI
Transcript : Qiagen N.V., Q1 2024 Earnings Call, Apr 30, 2024	04-30
Q1 2024 Results Conference Call Presentation: April 30, 2023	04-30	PU
Qiagen N : QIAGEN reports results for Q1 2024 ahead of outlook, on track to achieve full-year 2024 guidance	04-30	PU
QIAGEN NV : Jefferies remains Neutral	04-30	ZD
QIAGEN NV : UBS remains Neutral	04-30	ZD
QIAGEN NV : UBS remains Neutral	04-30	ZD
QIAGEN NV : UBS sticks Neutral	04-30	ZD

No results for this search

QIAGEN : A decent start to 2024; guidance unchanged

April 30, 2024 at 09:32 am